| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Mrz―26 |
Impact of pre-existing immunity on humoral and cellular responses to CoronaVac in SARS-CoV-2 variants: A focus on common human Coronaviruses |
|
| 2 |
[GO] |
2024―Dez―01 |
Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction |
|
| 3 |
[GO] |
2024―Sep―29 |
Evaluation of vaccine allergy safety track program to assess potential COVID-19 vaccine allergy: a cost-effectiveness analysis |
|
| 4 |
[GO] |
2024―Sep―01 |
Level of asthma control in children and adolescents before and during the COVID-19 pandemic |
|
| 5 |
[GO] |
2024―Mai―26 |
Host factors influencing variable symptoms of COVID-19 |
|
| 6 |
[GO] |
2024―Jan―21 |
Responses of primary human nasal epithelial cells to COVID-19 vaccine candidate |
|
| 7 |
[GO] |
2023―Nov―19 |
Global COVID-19 vaccination in infants and children: Effectiveness, safety, and challenges |
|
| 8 |
[GO] |
2023―Jul―23 |
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series |
|
| 9 |
[GO] |
2023―Feb―19 |
Humoral and cellular immune responses against SARS-CoV-2 variants of concern induced by heterologous CoronaVac/ChAdOx-1 versus homologous ChAdOx-1 vaccination in the elderly |
|
| 10 |
[GO] |
2023―Jan―22 |
Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis |
|
| 11 |
[GO] |
2023―Jan―08 |
COVID-19 Vaccine Allergy Safety Track (VAS-Track) pathway: real-world outcomes on vaccination rates and antibody protection |
|
| 12 |
[GO] |
2023―Jan―08 |
Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases |
|
| 13 |
[GO] |
2022―Nov―13 |
Disease activity of patients with chronic urticaria receiving COVID-19 vaccines |
|
| 14 |
[GO] |
2022―Mrz―14 |
Thrombosis with thrombocytopenia after the second ChAdOx1 nCoV-19 vaccination: A possible immunological mechanism independent of anti-platelet factor 4 antibody |
|
| 15 |
[GO] |
2022―Jan―15 |
A sero-epidemiological study after two waves of the COVID-19 epidemic |
|
| 16 |
[GO] |
2021―Nov―06 |
Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers |
|
| 17 |
[GO] |
2021―Jul―10 |
Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets |
|
| 18 |
[GO] |
2021―Mai―02 |
Asthma does not increase COVID-19 mortality and poor outcomes: A systematic review and meta-analysis |
|
| 19 |
[GO] |
2021―Mrz―06 |
Anxiety and depression in allergic rhinitis patients during COVID-19 pandemic in Wuhan, China |
|
| 20 |
[GO] |
2021―Jan―17 |
Social restriction versus herd immunity policies in the early phase of the SARS-CoV-2 pandemic: A mathematical modelling study |
|
| 21 |
[GO] |
2020―Sep―29 |
COVID-19 in children: Heterogeneity within the disease and hypothetical pathogenesis |
|
| 22 |
[GO] |
2020―Jul―20 |
Potential role of Bacillus Calmette-Guérin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects |
|
| 23 |
[GO] |
2020―Jun―30 |
Olfactory and gustatory dysfunctions in COVID-19 patients: A systematic review and meta-analysis |
|
| 24 |
[GO] |
2020―Jun―30 |
Smell and taste dysfunction in patients with SARS-CoV-2 infection: A review of epidemiology, pathogenesis, prognosis, and treatment options |
|
| 25 |
[GO] |
2020―Mrz―05 |
Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) |
|
| 26 |
[GO] |
2020―Feb―28 |
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic |
|
